Request Trial
17 August 2026NewsBiotechPaul Calvo

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Biotech
Masimo keeps $634m smartwatch award and moves to appeal
21 July 2026   Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.
Biotech
Arbutus takes Comirnaty LNP patent fight to Canada and UPC
20 July 2026   The biotech company has launched a trio of lawsuits against two vaccine makers, while announcing receipt of a $178 million sum from Moderna under a previous deal.
Biotech
Illumina ordered to recall products after German patent ruling
16 July 2026   A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US.


Editor's picks

Where Big Pharma is betting big in the M&A boom
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026

Editor's picks

Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Regulation & Industry
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026

More features

Former USPTO acting director takes the helm at C4IP
Novartis scores UK win in high-stakes Entresto fight
Invisalign maker secures first China win against clear aligner rival
Holland & Hart adds high-stakes patent litigation team from Ashurst Perkins Coie
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
Exclusive: ‘In the end, I did it my own way’ and became a UPC judge
Lilly mounts defence as generics circle Mounjaro and Zepbound
Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany